Journal
EXPERT REVIEW OF VACCINES
Volume 14, Issue 4, Pages 489-492Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/14760584.2015.1011135
Keywords
adjuvant; cancer vaccine; CD8 T cell; cytokine; DNA vaccine; immunotherapies; IL 33; isoform
Categories
Funding
- NIAID NIH HHS [P01 AI071739, P01 AI048241] Funding Source: Medline
Ask authors/readers for more resources
The identification and characterization of cytokine isoforms is likely to provide critical important new insight into immunobiology. Cytokine isoforms can provide additional diversity to their complex biological effects that participate in control and protection against different foreign pathogens. Recently, IL-33 has been identified as a proinflammatory cytokine having several different biologically active isoform products. Originally associated with Th2 immunity, new evidence now supports the role of two IL-33 isoforms to facilitate the generation of protective Th1 and CD8 T cell immunity against specific pathogens. Therefore, a better understanding of the IL-33 isoforms will inform us on how to utilize them to facilitate their development as tools as vaccine adjuvants for immune therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available